Oxford research moves to trials in 2027 as Andarta and Teva target cell metabolism to slow Parkinson's

A novel approach to slowing Parkinson's is heading into clinical trials, moving past temporary symptom relief to focus on cellular protection. Andarta Therapeutics has acquired the rights to Teva's fatty acid synthase inhibitor programme, backed by funding from The Michael J. Fox Foundation Therapeutic Pipeline Program, with human trials scheduled to start in early 2027. The science originates in Oxford, driven by research from Professor Richard Wade Martins. His work identified an enzyme called fatty acid synthase, or FASN, as a crucial driver of metabolic stress in vulnerable nerve cells. Brain cells depend on fats for structure and communication, but when this particular pathway runs in overdrive, cells become overwhelmed. By applying a molecular brake to FASN, the treatment aims to calm that metabolic strain, helping cells resist damage and survive longer. This venture bridges laboratory findings and practical drug development. The lead compound has already cleared official laboratory safety and toxicology hurdles, eliminating years of early groundwork. Under the agreement, Teva takes an equity stake in Andarta with an option to bring the medicine back into its commercial pipeline if human data shows success. Phase 1 safety trials will establish how the compound behaves in human biology. If the biological theory holds true in people, inhibiting FASN could provide a genuine tool to slow progression rather than just mask the daily effects of the condition.